Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Nautilus Biotechnology, Inc. (NAUT) had Income from Continuous Operations of $-15.03M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-15.03M |
|
-- |
|
-- |
|
$17.10M |
|
$-17.10M |
|
$2.06M |
|
$-15.03M |
|
$-15.03M |
|
$-15.03M |
|
|
Income from Continuous Operations |
$-15.03M |
$-15.03M |
|
$-15.03M |
|
$-17.10M |
|
$-15.90M |
|
126.20M |
|
126.20M |
|
$-0.12 |
|
$-0.12 |
|
| Balance Sheet Financials | |
$150.72M |
|
$3.73M |
|
$62.46M |
|
$213.19M |
|
$8.14M |
|
-- |
|
$23.96M |
|
$32.09M |
|
$181.09M |
|
$181.09M |
|
$181.09M |
|
126.31M |
|
| Cash Flow Statement Financials | |
$-27.29M |
|
$33.98M |
|
$0.11M |
|
$28.65M |
|
$35.46M |
|
$6.81M |
|
$3.88M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
18.52 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-27.90M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-8.30% |
|
-8.30% |
|
-7.05% |
|
-8.30% |
|
$1.43 |
|
$-0.22 |
|
$-0.22 |
|